Navigation Links
CryoCath Provides Update on Patent Infringement Lawsuit
Date:2/14/2008

http://www.cryocath.com Toronto Stock Exchange Symbol: CYT

MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, today provided an update on the enforcement of its patent portfolio.

Since its inception 13 years ago CryoCath has been, and continues to be the clear leader in innovation in the field of cryotherapy devices with cardiac applications and will continue to vigorously enforce its patent rights. CryoCath owns over 100 issued patents world-wide and has more than 100 patent applications pending. In the last five years, CryoCath has filed over 140 patent applications. Many of CryoCath's pending applications are expected to issue between 2008 and 2010, continuing to strengthen CryoCath's intellectual property position.

In October 2007, CryoCath filed a U.S. patent infringement suit against CryoCor, Inc. alleging infringement of six patents. Since that time, the United States Patent and Trademark Office (USPTO) has issued CryoCath two additional patents, U.S. Patent Nos. 7,303,554 and 7,318,821. CryoCath will amend its complaint to assert these patents in this patent infringement suit.

In early February 2008, CryoCath also filed a claim against CryoCor, alleging infringement of a ninth CryoCath patent, U.S. Patent # 5,147,355 entitled "Cryoablation Catheter and Method for Performing Cryoablation" issued to Friedman. Additionally CryoCath believes CryoCor and co-plaintiff AMS Research Corporation assert AMS's patents in their January 2008 action against CryoCath in a manner that illegally extends at least one patent beyond its scope. Therefore, CryoCath filed counterclaims alleging patent misuse, antitrust, and unfair competition. CryoCath believes CryoCor's case is without merit, and that it does not infringe the two patents asserted in the January 2008 action or the foreign counterparts.

Last month, the USPTO declared an Interference to determine the first to invent certain pre-cooling technology. By declaring the Interference, the USPTO allows CryoCath to get involved and present evidence to demonstrate CryoCath's priority to the technology. The USPTO operates under a system of "first-to-invent" rather than "first-to-file". Therefore, CryoCath now has the opportunity to present evidence that will establish it was indeed first-to-invent the pre-cooling technology at issue in the Interference and claimed in a subset of claims in the two CryoCath patents.

CryoCath's two patents at issue in the Interference, also asserted in the October 2007 action, claim priority to an application filed in January 1999. Consistent with the process of innovation, CryoCath invented this technology before it filed its January 1999 application and well before the August 2000 filing date relied on by CryoCor in requesting the Interference. CryoCath believes the USPTO will resolve the Interference in its favor.

CryoCath believes its strong infringement position for all six of its patents presently asserted, its two new patents that will be asserted in the October 2007 action, and its Friedman patent asserted in February 2008, will effectively protect CryoCath's business interests. CryoCath is also confident that the USPTO will conclude from CryoCath's participation in the Interference that CryoCath was the first to invent the technology at issue.

"Our team at CryoCath has worked long and hard to successfully build a strong intellectual property portfolio, creating the foundation on which our success is built," said Jan Keltjens, President and CEO of CryoCath. "We will defend our company's and stakeholders interests vigorously. Resolution of the ongoing dispute may take several years. We expect them to be resolved completely to our satisfaction and that CryoCath's leading efforts to create and commercialize our unique and innovative technology and to enforce our substantial intellectual property covering that technology will be fully recognized."

About CryoCath

CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.


'/>"/>
SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
4. CryoCath announces 2007 fourth quarter and fiscal year end financial results
5. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
6. CryoCath to Hold First Quarter 2008 Conference Call and Webcast
7. Study provides hope that some transplant patients could live free of antirejection drugs
8. Study provides hope that some transplant patients could live free of anti-rejection drugs
9. USAID Provides Additional Wildfire Assistance to Greece
10. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
11. New knock-out gene model provides molecular clues to breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale that teaches ... Kimberly Cordoves, a mother of three in Oklahoma City, and a devoted woman of faith. ... a book has been in the back of my mind for years, but actually doing ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots , ... from around the world, announces the launch of its newly redesigned website. The ... to research breakthroughs and trending news, vital information on upcoming virtual events and ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it will be co-hosting a ... innovative excipients and drug delivery solutions to health industries worldwide. The one day ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
(Date:1/19/2017)... , Jan. 19, 2017 This report on ... and future scenario of the global market. Large number ... consumption. Severe chronic constipation is a major side effect ... laxatives. Hence, novel targeted therapy has been prescribed to ... launch of targeted medicines, and growing awareness about the ...
(Date:1/19/2017)... BOSTON , Jan. 19, 2017  Stealth BioTherapeutics ... therapeutics to treat mitochondrial dysfunction, today announced new additions ... , M.D., as Chief Medical Officer, and Daniel ... Stealth announced that Jim Carr , Pharm.D. has ... "We are pleased to welcome Doug and Daniel ...
Breaking Medicine Technology: